Shane Keller, MD
Family Medicine · Austin, TXNPI 1194768911
Payments from drug & device makers
Across 167 payments — averaging $20.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$627
- Abbott$393
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$324
- AstraZeneca$322
- Novo Nordisk$185
- Pfizer$181
- plus $1K from 27 others
What the payments were for
- Food & beverage$3,481100%
- Education$120%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 27 | $627 |
| Abbott | 14 | $393 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 19 | $324 |
| AstraZeneca | 15 | $322 |
| Novo Nordisk | 7 | $185 |
| Pfizer | 8 | $181 |
| GSK | 10 | $160 |
| Amgen | 8 | $149 |
| Bayer | 6 | $100 |
| Lilly USA, LLC | 5 | $94 |
| Novartis | 5 | $93 |
| Corium, LLC | 3 | $92 |
| Gilead | 5 | $83 |
| Exact Sciences | 4 | $83 |
| Collegium Pharmaceutical, Inc. | 3 | $61 |
| Dexcom, Inc. | 3 | $60 |
| Antares Pharma, Inc. | 3 | $57 |
| Astellas Pharma US Inc | 3 | $51 |
| Kowa Pharmaceuticals America, Inc. | 3 | $50 |
| Johnson & Johnson(2 entities) | 2 | $43 |
| Medtronic | 2 | $38 |
| Inspire Medical Systems, Inc. | 1 | $38 |
| Nevro Corp. | 1 | $28 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $26 |
| Idorsia Pharmaceuticals US Inc | 1 | $23 |
| Phathom Pharmaceuticals, Inc. | 1 | $21 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $21 |
| Ironshore Pharmaceuticals Inc. | 1 | $20 |
| Almatica Pharma LLC | 1 | $19 |
| Acerus Pharmaceuticals Corporation | 1 | $18 |
| Tolmar, Inc. | 1 | $15 |
| Supernus Pharmaceuticals, Inc. | 1 | $14 |
| Romark Laboratories, LC | 1 | $3 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- OCTRODE$117
How this compares
$3,493 in reported general payments places this provider in the 80th percentile of 8,760 family medicine providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 55 | $90,569 |
| MounjaroTirzepatide | 73 | $89,602 |
| EliquisApixaban | 78 | $69,555 |
| TrulicityDulaglutide | 52 | $65,777 |
| JardianceEmpagliflozin | 51 | $65,056 |
| FarxigaDapagliflozin Propanediol | 39 | $43,292 |
| XareltoRivaroxaban | 23 | $25,331 |
| JanuviaSitagliptin Phosphate | 16 | $20,586 |
| KerendiaFinerenone | 16 | $16,302 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 18 | $15,327 |
| NeuproRotigotine | 12 | $9,524 |
| Incruse ElliptaUmeclidinium Bromide | 22 | $7,645 |
| Repatha SureclickEvolocumab | 14 | $7,591 |
| Dexlansoprazole DrDexlansoprazole | 15 | $7,323 |
| Airduo RespiclickFluticasone Propion/Salmeterol | 14 | $5,425 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $94 | $155,379125 claims |
| Novo NordiskOzempic | $185 | $90,56955 claims |
| PfizerEliquis | $181 | $69,55578 claims |
| AstraZenecaFarxiga | $322 | $43,29239 claims |
| GSKTrelegy Ellipta, Incruse Ellipta, Shingrix | $160 | $27,22459 claims |
| Johnson & JohnsonXarelto | $43 | $25,33123 claims |
| BayerKerendia | $100 | $16,30216 claims |
| AbbVieSynthroid | $627 | $2,39630 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 8,760 family medicine providers in Texas.
Other family medicine in Austin
- Cynthia BrinsonAustin$13.9M
- Gregg LucksingerAustin$11.4M
- Faith HolmesAustin$7.5M
- Gretchen CrookAustin$4.4M
- Matthew BrimberryAustin$3.8M
- Nomita KimAustin$3.3M
- Douglas DenhamSan Antonio$68.5M
- Vicki MillerPasadena$58.3M
- Hareshkumar BogharaDesoto$30.3M
- Earl MartinTomball$30.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.